{"title": "PPT - BIOMARCADORES DE TRATAMIENTO EN LA HEPATITIS C PowerPoint Presentation - ID:3351175", "author": "Gene", "url": "https://www.slideserve.com/gene/biomarcadores-de-tratamiento-en-la-hepatitis-c", "hostname": "slideserve.com", "description": "BIOMARCADORES DE TRATAMIENTO EN LA HEPATITIS C. Madrid, 13 de Mayo de 2011. Manuel Romero-G\u00f3mez. Unidad M\u00e9dico-Quir\u00fargica de Enfermedades Digestivas. Hospital Universitario de Valme. Universidad de Sevilla, Sevilla. Respuesta viral sostenida en genotipo 1. D 25% +Riba. D10 % +Peg.", "sitename": "SlideServe", "date": "2014-08-21", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "440 likes | 559 Views\nBIOMARCADORES DE TRATAMIENTO EN LA HEPATITIS C. Madrid, 13 de Mayo de 2011. Manuel Romero-G\u00f3mez. Unidad M\u00e9dico-Quir\u00fargica de Enfermedades Digestivas. Hospital Universitario de Valme. Universidad de Sevilla, Sevilla. Respuesta viral sostenida en genotipo 1. D 25% +Riba. D10 % +Peg.\nE N D\n[BIOMARCADORES DE TRATAMIENTO EN LA HEPATITIS C](https://image1.slideserve.com/3351175/biomarcadores-de-tratamiento-en-la-hepatitis-c-l.jpg) Madrid, 13 de Mayo de 2011 Manuel Romero-G\u00f3mez. Unidad M\u00e9dico-Quir\u00fargica de Enfermedades Digestivas. Hospital Universitario de Valme. Universidad de Sevilla, Sevilla. [Respuesta viral sostenida en genotipo 1](https://image1.slideserve.com/3351175/respuesta-viral-sostenida-en-genotipo-1-l.jpg) D25% +Riba D10% +Peg D30% +RGT McHutchinson et al. NEJM 1998; Manns et al. Lancet 2001; Fried et al. NEJM 2002; Hezode et al. NEJM 2009 [Predictive factors of SVR](https://image1.slideserve.com/3351175/predictive-factors-of-svr-l.jpg) Viral Genotype Viral load Fibrosis Metabolicabnormalities Genes [Factores predictivos de Respuesta](https://image1.slideserve.com/3351175/factores-predictivos-de-respuesta-l.jpg) Manns MP, et al. Nat Rev Drug Discov. 2007 Fried et al. NEJM 2002 Romero-G\u00f3mez et al. Liver Int 2011 [Genotype](https://image1.slideserve.com/3351175/genotype-l.jpg) Manns MP, et al. Nat Rev Drug Discov. 2007;6:991-1000. [Impact of IR & DM on hepatitis C](https://image1.slideserve.com/3351175/slide6-l.jpg) HCV-core NS5A Impairs SVR IR Degradation of IRS-1 Steatosis, Fibrosis Progression and HCC Improvement of viral fitness 1. Pazienza V et al. Hepatology 2007;45:1164 2. Sheikh MY, et al. Hepatology 2008;47:2127 3. Moucari R et al. Gastroenterology 2008;134:416 4. Romero-G\u00f3mez et al. Gastroenterology 2005;128:636 Conjeevaram HS et al. Hepatology 2007;45:80-87. Manolakopoulos S et al. BMC Gastroenterol 2007;7:17. [Insulin resistance and sustained virological response](https://image1.slideserve.com/3351175/slide7-l.jpg) Eslam M et al (personal communication) [Genes and SVR: IFN stimulated genes](https://image1.slideserve.com/3351175/slide8-l.jpg) INFalfa IFNAR1 \u2013 IFNAR2c JAK-------TyK PTPs SOCS P STAT MxA 5\u2019-2\u2019-OAS PKR APO-E4 [Antiviral proteins: MxA, 5\u20192\u2019-OAS, PKR](https://image1.slideserve.com/3351175/antiviral-proteins-mxa-5-2-oas-pkr-l.jpg) Weak associations without multivariate analysis Knapp S. Genes Immun 2003;4:411. [APO-E, IL-10, TGF-b1](https://image1.slideserve.com/3351175/apo-e-il-10-tgf-b1-l.jpg) Il-10: Haplotype extended: (108bp)(-2575T)(-2763C) (-1082A)(-819T)(-592A) Allele rare < 5% Associated with sustained response Confunding factors not excluded N=506 Mueller T. Hepatology 2003;38:1592 Yee LJ. Hepatology 2001;33:708. [HLA B 44](https://image1.slideserve.com/3351175/hla-b-44-l.jpg) HLA B44 is the most prevalente HLA in caucasians Multivariate analysis: Genotype non-1 [OR=2.42 (1.12 \u2013 5.55)] HLA B44+ [OR=4.84 (1.31-17.8)] N=105 (I+R) N=143 (IFN) Romero G\u00f3mez et al. Am J Gastroenterol 2003;98:1621. [IL28B polymorphisms & SVR](https://image1.slideserve.com/3351175/il28b-polymorphisms-svr-l.jpg) Ge et al. Nature 2009; [Influence of IL28b CC genotype on SVR in geno 1](https://image1.slideserve.com/3351175/influence-of-il28b-cc-genotype-on-svr-in-geno-1-l.jpg) %SVR Ge et al. Nature 2009; Thompson et al. Gastro2010; Rauch et al. Gastro 2010;Tanaka Nature Gen 2009; Suppiah et al. Nature Gen 2009;Montes-Cano et al. Hep2010 [Meta-analysis association SVR & genotype CC](https://image1.slideserve.com/3351175/meta-analysis-association-svr-genotype-cc-l.jpg) Romero-G\u00f3mez et al. Liver Int 2010 (in press) [IL28B polymorphisms: Distribution by race & SVR](https://image1.slideserve.com/3351175/slide17-l.jpg) Ge et al. Nature 2009; [IL28B mRNA expressionrs8099917](https://image1.slideserve.com/3351175/il28b-mrna-expression-rs8099917-l.jpg) Suppiah et al. Nat Gen 2009;41:1100 Tanaka et al. Nat Gen 2009;41:1105 [INF-l3 (IL28B): mechanism of action](https://image1.slideserve.com/3351175/inf-l3-il28b-mechanism-of-action-l.jpg) Asselah et al. J Hepatol 2010 Gad et al. JBC 2009 [N=731](https://image1.slideserve.com/3351175/slide20-l.jpg) SVC=69 CHC= 284 Healthy controls: 378 Montes-Cano et al. Hepatology 2010 [IL28b and SPONTANEOUS VIRAL CLEARANCE](https://image1.slideserve.com/3351175/slide21-l.jpg) P<0.0001 202/620 589/1015 Rauch et al. Gastro 2010; Thomas DL et al. Nature 2009;46:798 Tillmann et al. Gastro 2010; Montes-Cano et al. Hepatology 2010 [SVR & IL28b IN acute Hepatitis C](https://image1.slideserve.com/3351175/svr-il28b-in-acute-hepatitis-c-l.jpg) N=54 n=25 n=29 Grebely et al. Hepatology 2010 [IL28b and Spontaneous viral clearance](https://image1.slideserve.com/3351175/il28b-and-spontaneous-viral-clearance-l.jpg) SVR in treated acute Hep C N=54 3/32 15/47 rs 8099917 n=25 n=29 24 w Peg TT Recent HCV infection IL28b rs8099917 Peg GG/GT Gebrely et al. Hepatology 2010 [Influencia del genotipo de la IL28b seg\u00fan RVR Genotipo 1](https://image1.slideserve.com/3351175/influencia-del-genotipo-de-la-il28b-seg-n-rvr-genotipo-1-l.jpg) Thompson A et al. Gastro 2010 Mangia A et al. Gastro 2010 [N=268](https://image1.slideserve.com/3351175/influencia-il28b-en-genotipo-2-3-l.jpg) Genotipo 2/3 rs8099917 N=488 Genotipo 2 rs8099917 Influencia IL28b en genotipo 2/3 p=ns % RVS Yu et al. Hepatology 2011;53:7-13 Mangia et al Gastro 2010 Montes-Cano et al. Hepatology 2010 [Influencia del genotipo de la IL28b seg\u00fan genotipo viral y](https://image1.slideserve.com/3351175/influencia-del-genotipo-de-la-il28b-seg-n-genotipo-viral-y-rvr-l.jpg) RVR Thompson A et al. Gastro 2010 Mangia A et al. Gastro 2010 [IL28b en pacientes tratados con triple terapia:](https://image1.slideserve.com/3351175/slide28-l.jpg) IP + Peg + Riba [SPRINT-2: SVR by IL28B Polymorphism](https://image1.slideserve.com/3351175/sprint-2-svr-by-il28b-polymorphism-l.jpg) % SVR 50 64 63 77 44 55 33 116 67 103 82 115 10 37 23 42 26 44 Poordad et al. EASL 2011 [Triple terapia con boceprevir. ](https://image1.slideserve.com/3351175/slide30-l.jpg) SPRINT-2: RVS en funci\u00f3n PCR w 4 y 8. Estos resultados incluyen exclusivamente pacientes raza no negra. Poordad F, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. NEJM 2011; 364: 1195-1206. [REALIZE Study Design: Patients with IL28B Genotype Data](https://image1.slideserve.com/3351175/realize-study-design-patients-with-il28b-genotype-data-n-527-l.jpg) (n=527) T12/PR48 TVR + Peg-IFN + RBV Pbo + Peg-IFN + RBV Peg-IFN + RBV Follow-up n=212 Lead-in T12/PR48 Pbo + Peg-IFN + RBV TVR + Peg-IFN + RBV Peg-IFN + RBV Follow-up n=210 Pbo/PR48(control) Pbo + Peg-IFN + RBV Peg-IFN + RBV Follow-up n=105 72 4 0 12 16 48 8 Weeks SVR assessment Peg-IFN: Peg-IFN alfa-2a = 180\u03bcg/week; RBV = 1000\u20131200mg/day TVR = 750mg every 8 hours; Pbo = placebo Data from T12/PR48 and LI T12/PR48 arms were pooled since no differences were observed between TVR arms. Randomization was stratified by viral load and prior response. Stopping rules were applied for TVR (Weeks 4, 6, 8 for T12/PR48, Weeks 8, 10, 12 for LI T12/PR48) and PR (Weeks 12, 24, 36 for T12/PR48, Weeks 16, 24, 36 for LI T12/PR48) [Overall Baseline IL28B Genotype Distribution](https://image1.slideserve.com/3351175/overall-baseline-il28b-genotype-distribution-l.jpg) CC CT TT Patients (%) Pooled T12/PR4880/422 Pbo/ PR48 30/105 Pooled T12/PR4876/422 Pbo/ PR4817/105 Pooled T12/PR48266/422 Pbo/ PR4858/105 n/N= [Overall SVR Rates by IL28B Genotype](https://image1.slideserve.com/3351175/overall-svr-rates-by-il28b-genotype-l.jpg) CC CT TT Patients achieving SVR (%) Pooled T12/PR48 60/76 Pbo/ PR48 5/17 Pooled T12/PR48 49/80 Pbo/ PR48 4/30 Pooled T12/PR48 160/266 Pbo/ PR48 9/58 n/N= In a 2-step multivariate analysis exploring factors including: treatment group, IL28B genotype, prior response category, treatment/prior response interaction and other baseline characteristics including baseline HCV RNA, IL28B genotype did not have a significant impact on SVR (p=0.169 for CC, p=0.792 for TT) [SVR Rates by IL28B Genotype and PriorResponse](https://image1.slideserve.com/3351175/svr-rates-by-il28b-genotype-and-prior-response-l.jpg) Prior relapsers Prior partial responders Prior null responders Pooled T12/PR48 (n=134) Pbo/PR48 (n=33) Pooled T12/PR48 (n=209) Pbo/PR48 (n=52) Pooled T12/PR48 (n=79) Pbo/PR48 (n=20) Patients achieving SVR (%) n/a TT TT TT CC CT CC CT CC CT n/N= 4/12 100/117 3/10 5/8 1/5 2/10 10/14 4/10 27/92 1/15 51/58 6/30 29/34 33/57 0/5 1/18 10/32 [Camino hacia la predicci\u00f3n de respuesta viral sostenida](https://image1.slideserve.com/3351175/slide35-l.jpg) SVR 28% Genotype CC 35% 80% N=474 (G1/4) N=268 (G2/3) 56% Genotype CT 50% 25% 50% Genotype TT 15% 3% 20% St\u00e4ttermayer AF et al. CGH 2011 (in press) Mangia et al. Gastro 2010 Romero G\u00f3mez et al. Liver Int 2011 (in press) [Several genetic markers in 19q13.3 (IL28B)](https://image1.slideserve.com/3351175/several-genetic-markers-in-19q13-3-il28b-l.jpg) Illumina Affymetrix [Interaction between IL28B & fibrosis progression](https://image1.slideserve.com/3351175/slide37-l.jpg) p=ns % IL28b gen CC [Interaction between IL28B & viral load](https://image1.slideserve.com/3351175/slide38-l.jpg) p=ns Viral load (log/ml) Del Campo et al AASLD 2010 [Association between IL28B and metabolic disturbances](https://image1.slideserve.com/3351175/slide39-l.jpg) P=0.001 P=0.1 P=0.01 P=0.06 mg/dl P=0.1 Del Campo et al AASLD 2010 [Association between IL28b & lipid and glucose metabolism](https://image1.slideserve.com/3351175/slide40-l.jpg) mg/dl Del Campo et al AASLD 2010 [Association between SVR & lipid and glucose metabolism](https://image1.slideserve.com/3351175/slide41-l.jpg) mg/dl Del Campo et al AASLD 2010 [New Predictors: IL28B Genotype a Strong Predictor of SVR](https://image1.slideserve.com/3351175/new-predictors-il28b-genotype-a-strong-predictor-of-svr-with-pegifn-rbv-l.jpg) With PegIFN/RBV Whites (n = 871) Factor Associated With SVR Odds Ratio (95% CI) IL28B rs12979860 genotype (CC vs TT) 7.3 Baseline HCV RNA (< vs \u2265 600,000 IU/mL) 6.1 5.6 Baseline fibrosis (METAVIR F0-F2 vs F3-F4) 0.1 1.0 10.0 Ge D, et al. Nature. 2009;461:399-401. [No RVR](https://image1.slideserve.com/3351175/slide43-l.jpg) IP+Peg+RBV RVR Tratamiento convencional con IFN pegilado y RBV", "language": null, "image": "https://cdn1.slideserve.com/3351175/biomarcadores-de-tratamiento-en-la-hepatitis-c-n.jpg", "pagetype": "article", "links": ["\\", "#", "/presentations", "/presentations", "/topics", "/updates", "/featured", "/powerpoint-templates", "/create?utm_source=slideserve&utm_medium=website&utm_campaign=presentation+creator", "/article-stories", "/online-survey", "/online-quiz", "/lead-generation", "/create?type=ebook&utm_source=slideserve&utm_medium=website&utm_campaign=ebook+creator", "https://www.slideserve.com/create?utm_source=slideserve&utm_medium=website&utm_campaign=presentation+creator", "/pro", "/upload", "/search/il28b-ppt-presentation", "/search/pbo-pr48-ppt-presentation", "/search/gastro-2010-ppt-presentation", "/search/t12-pr48-ppt-presentation", "/search/li-t12-pr48-ppt-presentation", "/search/baseline-il28b-genotype-distribution-ppt-presentation", "/gene", "https://image1.slideserve.com/3351175/biomarcadores-de-tratamiento-en-la-hepatitis-c-l.jpg", "https://image1.slideserve.com/3351175/respuesta-viral-sostenida-en-genotipo-1-l.jpg", "https://image1.slideserve.com/3351175/predictive-factors-of-svr-l.jpg", "https://image1.slideserve.com/3351175/factores-predictivos-de-respuesta-l.jpg", "https://image1.slideserve.com/3351175/genotype-l.jpg", "https://image1.slideserve.com/3351175/slide6-l.jpg", "https://image1.slideserve.com/3351175/slide7-l.jpg", "https://image1.slideserve.com/3351175/slide8-l.jpg", "https://image1.slideserve.com/3351175/antiviral-proteins-mxa-5-2-oas-pkr-l.jpg", "https://image1.slideserve.com/3351175/apo-e-il-10-tgf-b1-l.jpg", "https://image1.slideserve.com/3351175/hla-b-44-l.jpg", "https://image1.slideserve.com/3351175/slide13-l.jpg", "https://image1.slideserve.com/3351175/il28b-polymorphisms-svr-l.jpg", "https://image1.slideserve.com/3351175/influence-of-il28b-cc-genotype-on-svr-in-geno-1-l.jpg", "https://image1.slideserve.com/3351175/meta-analysis-association-svr-genotype-cc-l.jpg", "https://image1.slideserve.com/3351175/slide17-l.jpg", "https://image1.slideserve.com/3351175/il28b-mrna-expression-rs8099917-l.jpg", "https://image1.slideserve.com/3351175/inf-l3-il28b-mechanism-of-action-l.jpg", "https://image1.slideserve.com/3351175/slide20-l.jpg", "https://image1.slideserve.com/3351175/slide21-l.jpg", "https://image1.slideserve.com/3351175/svr-il28b-in-acute-hepatitis-c-l.jpg", "https://image1.slideserve.com/3351175/il28b-and-spontaneous-viral-clearance-l.jpg", "https://image1.slideserve.com/3351175/il28b-y-respuesta-viral-r-pida-l.jpg", "https://image1.slideserve.com/3351175/influencia-del-genotipo-de-la-il28b-seg-n-rvr-genotipo-1-l.jpg", "https://image1.slideserve.com/3351175/influencia-il28b-en-genotipo-2-3-l.jpg", "https://image1.slideserve.com/3351175/influencia-del-genotipo-de-la-il28b-seg-n-genotipo-viral-y-rvr-l.jpg", "https://image1.slideserve.com/3351175/slide28-l.jpg", "https://image1.slideserve.com/3351175/sprint-2-svr-by-il28b-polymorphism-l.jpg", "https://image1.slideserve.com/3351175/slide30-l.jpg", "https://image1.slideserve.com/3351175/realize-study-design-patients-with-il28b-genotype-data-n-527-l.jpg", "https://image1.slideserve.com/3351175/overall-baseline-il28b-genotype-distribution-l.jpg", "https://image1.slideserve.com/3351175/overall-svr-rates-by-il28b-genotype-l.jpg", "https://image1.slideserve.com/3351175/svr-rates-by-il28b-genotype-and-prior-response-l.jpg", "https://image1.slideserve.com/3351175/slide35-l.jpg", "https://image1.slideserve.com/3351175/several-genetic-markers-in-19q13-3-il28b-l.jpg", "https://image1.slideserve.com/3351175/slide37-l.jpg", "https://image1.slideserve.com/3351175/slide38-l.jpg", "https://image1.slideserve.com/3351175/slide39-l.jpg", "https://image1.slideserve.com/3351175/slide40-l.jpg", "https://image1.slideserve.com/3351175/slide41-l.jpg", "https://image1.slideserve.com/3351175/new-predictors-il28b-genotype-a-strong-predictor-of-svr-with-pegifn-rbv-l.jpg", "https://image1.slideserve.com/3351175/slide43-l.jpg", "/zlhna/tratamiento-de-la-hepatitis-b-curso-de-actualizaci-n-en-hepatitis-virales-somamfyc-madrid-20-21-de-octubre-de-2011", "/alexavier/tratamiento-de-la-hepatitis-c-en-pacientes-coinfectados-por-vih-importancia-de-la-cin-tica-viral", "/creola/diagnose-van-hepatitis-b-en-hepatitis-c", "/vsantana/biomarcadores-de-tratamiento-en-la-hepatitis-c-powerpoint-ppt-presentation", "/leahyj/tratamiento-de-la-hepatitis-b-curso-de-actualizaci-n-en-hepatitis-virales-powerpoint-ppt-presentation", "//www.slideserve.com", "//fr.slideserve.com", "/about", "/privacy", "/dmca", "https://blog.slideserve.com", "/contact", "https://www.facebook.com/SlideServe", "https://twitter.com/slideserve", "https://www.youtube.com/user/SlideServe", "https://www.pinterest.com/slideserve/"]}